APOA1 and metabolic dysfunction-associated steatotic liver disease: Despite these limitations, evidence from both in vivo and in vitro studies provides a coherent framework supporting the importance of the apoA-I–microbiota–PPA pathway in ameliorating MASLD and highlights its potential as a therapeutic target.